All In Biotech

Drug Trial Radar · NCT01241591

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Dec 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,101 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,101

Actual

Start

Nov 2010

Primary completion

Jan 2013

Study completion Jan 2013

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 16, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.

Conditions

  • Psoriasis

Interventions

  • CP 690,550 5 mgDrug

    CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks

  • CP 690,550 10 mgDrug

    CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks

  • Etanercept 50 mgBiological

    Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks

  • PlaceboOther

    Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 12Time frame: Week 12
  2. Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12Time frame: Week 12

Locations

122 sites in 26 countries. Site status is shown where the registry gives one.

  • Centro de Investigaciones Dermatologicas

    Buenos Aires, Argentina

  • IMAI (Instituto Medico de Asistencia e Investigaciones)

    Buenos Aires, Argentina

  • Centro de Investigaciones Dermatologicas

    Buenos Aires, C1114aap, Argentina

  • LKH Feldkirch Abteilung fuer Dermatologie und Venerologie

    Feldkirch, Austria

  • LKH Innsbruck Universitaetsklinik fuer Dermatologie und Venerologie

    Innsbruck, Austria

  • LKH Salzburg, Landesklinik fuer Dermatologie

    Salzburg, Austria

  • Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhuegel

    Vienna, Austria

  • Cliniques universitaires Saint-Luc

    Brussels, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Department for skin and venerial diseases, Clinical Center University of Sarajevo

    Sarajevo, Bosnia and Herzegovina

  • Universitetska Mnogoprofilna Bolnitsa Za Aktivno Lechenie- Dr Georgi Stranski- Pleven

    Pleven, Bulgaria

  • Tsentar za kozhno-venericheski zaboliavania" EOOD

    Sofia, Bulgaria

  • Mnogoprofilna Bolnitsa Za Aktivno Lechenie- Tokuda Bolnitsa Sofia- Sofia

    Sofia, Bulgaria

  • Universitetska mnogoprofilna bolnitsa za aktivno lechenie- Alexandrovska- Sofia

    Sofia, Bulgaria

  • MBAL na Voennomeditsinska akademia- Sofia

    Sofia, Bulgaria

  • Clinica Dermovein S.A.

    Santiago, Chile

  • Hospital Clinico Universidad de Chile, Departamento Dermatologia

    Santiago, Chile

  • Clinica Davila

    Santiago, Rm 8431657, RM, Chile

  • Centro de Especialidades Dermatologicas

    Viña del Mar, Valparaiso, Chile

  • Reumalab S.A.S.

    Medellín, Antioquia, Colombia

  • Centro Integral de Reumatología del Caribe Circaribe S.A

    Barranquilla, Atlántico, Colombia

  • Centro de Investigacion Clinica de la Universidad del Rosario

    Bogota, Cundinamarca, Colombia

  • Riesgo de Fractura S.A.

    Bogota, Cundinamarca, Colombia

  • Medicity S.A.S

    Bucaramanga, Santander Department, Colombia

  • Department of Dermatovenerology, University Hospital Center Osijek

    Osijek, Croatia

  • Dermatovenerological Clinic, University hospital center "Sestre milosrdnice"

    Zagreb, Croatia

  • Department of dermatovenerology, University Hospital Center Zagreb

    Zagreb, Croatia

  • Nemocnice Ceske Budejovice, a.s.

    České Budějovice, Czechia

  • FN Kradec Kralove

    Hradec Králové, Czechia

  • Fakultni nemocnice Plzen

    Plzen - Bory, Czechia

  • Kozni ordinace

    Prague, Czechia

  • Kralska zdravotni a.s., Masarykovy nemocnice o.z.

    Ústí nad Labem, Czechia

  • Kralska zdravotni

    Ústí nad Labem, Czechia

  • Department of Dermatology, Aarhus University Hospital

    Aarhus C, Denmark

  • Bispebjerg Hospital, University of Copenhagen

    Copenhagen NV, Denmark

  • Hudklinikken Herning

    Herning, Denmark

  • CHU de Besancon - Hopital Saint Jacques

    Besançon, France

  • Hopital Ambroise Pare, Service de Dermatologie

    Boulogne, France

  • Chu Morvan

    Brest Cédex, France

  • Hopital Dupuytren

    Limoges, France

Showing 40 of 122 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.